Cargando…

HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases

Histone deacetylase (HDAC) inhibitors are powerful epigenetic regulators that have enormous therapeutic potential and have pleiotropic effects at the cellular and systemic levels. To date, HDAC inhibitors are used clinically for a wide variety of disorders ranging from hematopoietic malignancies to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hull, Elizabeth E., Montgomery, McKale R., Leyva, Kathryn J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4983322/ https://www.ncbi.nlm.nih.gov/pubmed/27556043 http://dx.doi.org/10.1155/2016/8797206

Ejemplares similares

Alterations in the glycome after HDAC inhibition impact oncogenic potential in epigenetically plastic SW13 cells
por: Montgomery, McKale R., et al.
Publicado: (2019)

Epigenetic Regulation of the Biosynthesis & Enzymatic Modification of Heparan Sulfate Proteoglycans: Implications for Tumorigenesis and Cancer Biomarkers
por: Hull, Elizabeth E., et al.
Publicado: (2017)

Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition
por: Davis, McKale R., et al.
Publicado: (2016)

Epigenetic Gene Regulation by Dietary Compounds in Cancer Prevention
por: Montgomery, McKale, et al.
Publicado: (2019)

HDAC inhibition induces EMT and alterations in cellular iron homeostasis to augment ferroptosis sensitivity in SW13 cells
por: Oliveira, Thais, et al.
Publicado: (2021)

A Hybrid Epithelial to Mesenchymal Transition in Ex Vivo Cutaneous Squamous Cell Carcinoma Tissues
por: Pulford, Christopher S., et al.
Publicado: (2022)

Iron regulatory proteins: players or pawns in ferroptosis and cancer?
por: Cardona, Cameron J., et al.
Publicado: (2023)

Food Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart Failure
por: Evans, Levi W., et al.
Publicado: (2018)

Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer
por: Li, Yuxin, et al.
Publicado: (2020)

Targeting Epigenetic Regulators with HDAC and BET Inhibitors to Modulate Muscle Wasting
por: Nevi, Lorenzo, et al.
Publicado: (2023)

The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity
por: Liu, Geng, et al.
Publicado: (2023)

Influence of microRNA on the Maintenance of Human Iron Metabolism
por: Davis, McKale, et al.
Publicado: (2013)

HDAC Inhibitor-Mediated Epigenetic Regulation of Glaucoma-Associated TGFβ2 in the Trabecular Meshwork
por: Bermudez, Jaclyn Y., et al.
Publicado: (2016)

Biological Effects of HDAC Inhibitors Vary with Zinc Binding Group: Differential Effects on Zinc Bioavailability, ROS Production, and R175H p53 Mutant Protein Reactivation
por: Flores, Brianna M., et al.
Publicado: (2023)

Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells
por: Tay, Rong En, et al.
Publicado: (2020)

Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro‐adipogenic progenitors
por: Consalvi, Silvia, et al.
Publicado: (2022)

Distinct TP53 Mutation Subtypes Differentially Influence Cellular Iron Metabolism
por: Clarke, Stephen L., et al.
Publicado: (2019)

The anticancer effects of HDAC inhibitors require the immune system
por: West, Alison C, et al.
Publicado: (2014)

HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases
por: Shanmugam, Geetha, et al.
Publicado: (2021)

Short communication: TNF-α and IGF-1 regulates epigenetic mechanisms of HDAC2 and HDAC10
por: Jiang, Wanlin, et al.
Publicado: (2022)

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
por: Mayr, Christian, et al.
Publicado: (2021)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014)

HDAC Inhibition to Prime Immune Checkpoint Inhibitors
por: Borcoman, Edith, et al.
Publicado: (2021)

Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation
por: Cini, Elena, et al.
Publicado: (2018)

Correction: Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells
por: Tay, Rong En, et al.
Publicado: (2020)

Brain Magnetic Resonance Imaging Phenome-Wide Association Study With Metal Transporter Gene SLC39A8
por: Hermann, Evan R., et al.
Publicado: (2021)

Differences in Antioxidant and Lipid Handling Protein Expression Influence How Cells Expressing Distinct Mutant TP53 Subtypes Maintain Iron Homeostasis
por: Cardona, Cameron J., et al.
Publicado: (2022)

Proteomic Analysis of HDAC3 Selective Inhibitor in the Regulation of Inflammatory Response of Primary Microglia
por: Xia, Mingxu, et al.
Publicado: (2017)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
por: King, Jacob, et al.
Publicado: (2021)

HDAC inhibitors and their potential applications to glioblastoma therapy
por: Adamopoulou, Eleni, et al.
Publicado: (2013)

Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases
por: McConnell, Melanie J., et al.
Publicado: (2015)

Epigenetic master regulators HDAC1 and HDAC5 control pathobiont Enterobacteria colonization in ileal mucosa of Crohn’s disease patients
por: Chervy, Mélissa, et al.
Publicado: (2022)

Distinct TP53 Mutation Types Exhibit Increased Sensitivity to Ferroptosis Independently of Changes in Iron Regulatory Protein Activity
por: Thompson, Laurie R., et al.
Publicado: (2020)

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
por: Yoon, Somy, et al.
Publicado: (2016)

Epigenetic modulation with oral histone deacetylase (HDAC) inhibitor as a new treatment option in JIA
por: Vojinovic, J, et al.
Publicado: (2011)

Remodeling of retrotransposon elements during epigenetic induction of adult visual cortical plasticity by HDAC inhibitors
por: Lennartsson, Andreas, et al.
Publicado: (2015)

Epigenetic Regulation of Immune and Inflammatory Responses in Rheumatoid Arthritis
por: Chen, Qi, et al.
Publicado: (2022)

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy
por: Nakashima, Hiroshi, et al.
Publicado: (2015)

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
por: Maccallini, Cristina, et al.
Publicado: (2022)

Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
por: Blaszczak, Wiktoria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4rs0jvuriktbddqgngcs08d10r